LGDN Stock Overview
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LGDN from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Ligand Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$90.50 |
| 52 Week High | US$120.00 |
| 52 Week Low | US$72.50 |
| Beta | 0.76 |
| 1 Month Change | 1.12% |
| 3 Month Change | -20.61% |
| 1 Year Change | 15.29% |
| 3 Year Change | 14.91% |
| 5 Year Change | -5.41% |
| Change since IPO | 8.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| LGDN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.1% | -6.6% | 0.8% |
| 1Y | 15.3% | -27.7% | 14.6% |
Return vs Industry: LGDN exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: LGDN matched the German Market which returned 14.6% over the past year.
Price Volatility
| LGDN volatility | |
|---|---|
| LGDN Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: LGDN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LGDN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 68 | Todd Davis | www.ligand.com |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
Ligand Pharmaceuticals Incorporated Fundamentals Summary
| LGDN fundamental statistics | |
|---|---|
| Market cap | €1.81b |
| Earnings (TTM) | -€118.95m |
| Revenue (TTM) | €162.78m |
11.1x
P/S Ratio-15.2x
P/E RatioIs LGDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGDN income statement (TTM) | |
|---|---|
| Revenue | US$181.49m |
| Cost of Revenue | US$78.58m |
| Gross Profit | US$102.91m |
| Other Expenses | US$235.53m |
| Earnings | -US$132.62m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.87 |
| Gross Margin | 56.70% |
| Net Profit Margin | -73.07% |
| Debt/Equity Ratio | 0% |
How did LGDN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 04:30 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ligand Pharmaceuticals Incorporated is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Robert Wasserman | Benchmark Company |
| Gene Mack | Brean Capital |